Percentage of cells in CD90+/− subsets of CD34+ bone marrow progenitors in G0 and S/G2/M phases of the cell cycle in donors and recipients
ID . | CD34+subset . | Donor . | Recipient . | ||
---|---|---|---|---|---|
G0/S/G2/M . | 2 mo3-150G0/S/G2/M . | 6 mo3-150G0/S/G2/M . | 12 mo G0/S/G2/M . | ||
1 | CD90+ | 92/3 | 49/15 | — | — |
CD90− | 69/7 | 71/9 | — | — | |
2 | CD90+ | 85/5 | 37/13 | — | 74/6 |
CD90− | 65/10 | 33/12 | — | 46/8 | |
3 | CD90+ | 58/6 | 30/19 | — | — |
CD90− | 33/7 | 49/11 | — | — | |
4 | CD90+ | 69/4 | 55/13 | 65/15 | — |
CD90− | 38/12 | 34/10 | 22/12 | — | |
5 | CD90+ | 91/2 | — | 41/22 | 64/12 |
CD90− | 81/7 | — | 28/12 | 37/12 | |
6 | CD90+ | 65/5 | — | 21/19 | 80/9 |
CD90− | 29/8 | — | 53/10 | 45/13 | |
7 | CD90+ | 58/6 | — | 49/14 | 48/11 |
CD90− | 33/7 | — | 29/12 | 40/8 | |
8 | CD90+ | 80/5 | — | 27/15 | 38/15 |
CD90− | 60/13 | — | 27/11.5 | 15.5/10.5 | |
9 | CD90+ | 77/5 | — | — | 49/15 |
CD90− | 56/10 | — | — | 60/9 | |
10 | CD90+ | 62/6 | — | — | 61/13 |
CD90− | 18/12 | — | — | 49/10 | |
11 | CD90+ | 74/3 | — | — | 60.5/10.5 |
CD90− | 27/9 | — | — | 33/12 | |
12 | CD90+ | 58/7 | — | — | 63/16 |
CD90− | 38/9 | — | — | 18/16 | |
13 | CD90+ | 58/4 | — | — | — |
CD90− | 17/10 | — | — | ||
14 | CD90+ | 71/2 | — | — | — |
CD90− | 35/8 | — | — | — | |
15 | CD90+ | 90/2 | — | — | 72/7 |
CD90− | 62/9 | — | — | 23/10 | |
16 | CD90+ | — | — | 48/11 | — |
CD90− | — | — | 40/10 | — | |
17 | CD90+ | — | — | 49/15 | — |
CD90− | — | — | 30/11 | — | |
18 | CD90+ | — | — | 55/16 | — |
CD90− | — | — | 36/11 | — | |
Mean (SD) | CD90+ | 72.5 (12.8)/4.3 (1.6)3-151,3-152 | 42.4 (12.3)/15.7 (3.1)3-151,3-153 | 61 (13)/11.5 (3.4)3-152,3-153 | |
Mean (SD) | CD90− | 44 (19.8)/9.2 (2)3-155 | 38.5 (13.9)/11 (1)3-155 | 36.7 (14.4)/10.9 (2.5) |
ID . | CD34+subset . | Donor . | Recipient . | ||
---|---|---|---|---|---|
G0/S/G2/M . | 2 mo3-150G0/S/G2/M . | 6 mo3-150G0/S/G2/M . | 12 mo G0/S/G2/M . | ||
1 | CD90+ | 92/3 | 49/15 | — | — |
CD90− | 69/7 | 71/9 | — | — | |
2 | CD90+ | 85/5 | 37/13 | — | 74/6 |
CD90− | 65/10 | 33/12 | — | 46/8 | |
3 | CD90+ | 58/6 | 30/19 | — | — |
CD90− | 33/7 | 49/11 | — | — | |
4 | CD90+ | 69/4 | 55/13 | 65/15 | — |
CD90− | 38/12 | 34/10 | 22/12 | — | |
5 | CD90+ | 91/2 | — | 41/22 | 64/12 |
CD90− | 81/7 | — | 28/12 | 37/12 | |
6 | CD90+ | 65/5 | — | 21/19 | 80/9 |
CD90− | 29/8 | — | 53/10 | 45/13 | |
7 | CD90+ | 58/6 | — | 49/14 | 48/11 |
CD90− | 33/7 | — | 29/12 | 40/8 | |
8 | CD90+ | 80/5 | — | 27/15 | 38/15 |
CD90− | 60/13 | — | 27/11.5 | 15.5/10.5 | |
9 | CD90+ | 77/5 | — | — | 49/15 |
CD90− | 56/10 | — | — | 60/9 | |
10 | CD90+ | 62/6 | — | — | 61/13 |
CD90− | 18/12 | — | — | 49/10 | |
11 | CD90+ | 74/3 | — | — | 60.5/10.5 |
CD90− | 27/9 | — | — | 33/12 | |
12 | CD90+ | 58/7 | — | — | 63/16 |
CD90− | 38/9 | — | — | 18/16 | |
13 | CD90+ | 58/4 | — | — | — |
CD90− | 17/10 | — | — | ||
14 | CD90+ | 71/2 | — | — | — |
CD90− | 35/8 | — | — | — | |
15 | CD90+ | 90/2 | — | — | 72/7 |
CD90− | 62/9 | — | — | 23/10 | |
16 | CD90+ | — | — | 48/11 | — |
CD90− | — | — | 40/10 | — | |
17 | CD90+ | — | — | 49/15 | — |
CD90− | — | — | 30/11 | — | |
18 | CD90+ | — | — | 55/16 | — |
CD90− | — | — | 36/11 | — | |
Mean (SD) | CD90+ | 72.5 (12.8)/4.3 (1.6)3-151,3-152 | 42.4 (12.3)/15.7 (3.1)3-151,3-153 | 61 (13)/11.5 (3.4)3-152,3-153 | |
Mean (SD) | CD90− | 44 (19.8)/9.2 (2)3-155 | 38.5 (13.9)/11 (1)3-155 | 36.7 (14.4)/10.9 (2.5) |
Percentage of cells in G1 = 100 − (%G0 + %S/G2/M).
Results from 2 and 6 months combined for comparative analyses (for R4, a mean of 2 and 6 month results derived).
P = .0008 (G0) and < .0001 (S/G2/M) (by two-tailed paired t test).
P = .04 (S/G2/M) (by two-tailed paired t test).
P = .04 (G0) and < .0001 (S/G2/M) (by two-tailed paired t test).
P = .04 (S/G2/M) (by two-tailed paired t test).